Trinity Biotech earnings date
Trinity Biotech (TRB0) Q3 2024 Earnings Report
DE:TRB0 Q3 2024 EPS Results
- Actual EPS
- -EUR 12.54
- Consensus EPS
- -EUR 14.77
- Beat/Miss
- Beat by +EUR 2.24
- One Year Ago EPS
- -EUR 23.94
DE:TRB0 Q3 2024 Revenue Results
- Actual Revenue
- EUR 13.86M
- Expected Revenue
- EUR 15.05M
- Beat/Miss
- Missed by -EUR 1.19M
- YoY Revenue Growth
- +12.21%
Earnings Announcement Details
- Quarter
- Q3 2024
- Date
- 11/15/2024
- Time
- Before Open
- Conference Call
- Friday, November 15, 2024
Trinity Biotech's next earnings date is estimated for December 10, 2026, based on past reporting schedules.
Q3 2024 Earnings Call Audio
Q3 2024 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2024 Earnings Call Summary
The earnings call reflected a company in transition, with significant improvements in revenue growth and cost reduction measures. However, challenges remain, particularly in the hemoglobin segment and overall net loss, indicating a mixed outlook.
During Trinity Biotech's Q3 2024 earnings call, the company reiterated its guidance for 2024, projecting TrinScreen HIV sales revenue of approximately $10 million and annualized run rate revenues of around $75 million by Q2 2025. The company reported a 3% year-on-year revenue growth, reaching $15.2 million for Q3 2024, primarily driven by a 60% increase in point-of-care revenues due to TrinScreen sales. Operating loss improved by 51% to $2.2 million before restructuring and impairment charges. The company aims to achieve approximately $20 million of annualized run rate EBITDASO by Q2 2025 through comprehensive transformation initiatives, including cost reductions and operational efficiencies.
- Revenue Growth in Q3 2024The company's revenues for Q3 2024 were $15.2 million, representing a 3% increase compared to Q3 2023. This growth was primarily driven by a 60% increase in point-of-care revenue.
- TrinScreen HIV Sales ProjectionTrinity Biotech reiterated its guidance for TrinScreen sales of approximately $10 million for the full year 2024, reflecting strong market demand.
- Reduction in Operating LossThe operating loss before restructuring and impairment charges decreased to $2.2 million from $4.5 million in Q3 2023, marking a 51% improvement.
- NASDAQ Listing Compliance AchievedThe company successfully addressed NASDAQ listing deficiencies, removing an important overhang on its stock.
- Cost Reduction InitiativesSG&A expenses decreased by $1.2 million to $6.5 million in Q3 2024, showcasing effective cost reduction measures.
DE:TRB0 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Dec 10, 2026 | 2026 (Q3) | ―- | -0.25 | ― | ― |
| Sep 03, 2026 | 2026 (Q2) | ―- | -0.3 | ― | |
| May 27, 2026 | 2026 (Q1) | ―- | -0.44 | ― | |
| Apr 08, 2026 | 2025 (Q4) | ―-6.25 | -13.16 | 52.53% (+6.91) | |
| Dec 11, 2025 | 2025 (Q3) | ―-0.25 | -0.42 | 40.17% (+0.17) | |
| Sep 02, 2025 | 2025 (Q2) | -0.47- | -0.65 | ― | |
| May 21, 2025 | 2025 (Q1) | ―- | ― | ― | |
| May 15, 2025 | 2024 (Q4) | ―-13.16 | -10.23 | -28.65% (-2.93) | |
| Nov 15, 2024 | 2024 (Q3) | -14.77-12.54 | -23.94 | 47.64% (+11.40) | |
| Aug 14, 2024 | 2024 (Q2) | -18.33-19.53 | -65.55 | 70.21% (+46.02) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

